BÜHLMANN’s Kinase Inhibition Assay Testing Potency and Efficacy of Inhibitors of PI3K δ, PI3K γ, BTK and SYK Activity Biomarker assays are developed specifically for pharmacokinetic and pharmacodyamic (PK/PD) models during drug discovery and are often used to test efficacy and toxicity. Inhibitors of PI3K, BTK and SYKpathways are a large focus for pharmaceutical companies
- info@buhlmannlabs.ch
- +41 61 487 12 12
Blog Archives
Interview with Dr. Christian Reinhard at UEGW 2016 about the first 18 months of market experience with IBDoc® At this year’s UEGW in Vienna, Dr. Christian Reinhard presented data collected from the first 18 months of market experience with IBDoc®. In the biomarker session on Tuesday 18th of October the IBDoc® product manager at BÜHLMANN
Interview with Yvonne Schallberger, Bioanalytica Lucerne Deutsch Français Italiano English INTERVIEW MIT YVONNE SCHALLBERGER, BIOANALYTICA, LUZERN Frau Schallberger, Sie haben sich kürzlich für den neuen BÜHLMANN fCAL® turbo Test entschieden, welcher Calprotectin aus Stuhl innerhalb von ca. 10 Minuten in Random Access auf allen gängigen Klinisch Chemischen Analysern detektiert. Warum? Es war ein Wunsch,
Social Links